Latest news for GPL Hldgs (OTC:GPLL) Stock

GPL Holdings Inc is a biopharmaceutical company dedicated to developing new therapies and to providing low-cost quality healthcare products including prescription drugs, non- prescription drugs, medical supplies, dental supplies, medical equipment, and dental equipment.

GPL Holdings Inc

Rivian Automotive Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIVN#NASDAQ">RIVN</a>) shares are trading higher by 2.75% to $17.21 Monday morning, despite a lack of company-specific news for the session. The market is rising due to expectations of a positive earnings season, with investors optimistic about strong financial reports and a potential <a href="https://www.benzinga.com/news/earnings/24/07/39880691/wall-street-set-to-rebound-amid-hopes-of-strong-earnings-political-uncertainty-caused-by-biden-step">Federal Reserve rate cut</a>.
Additionally, the recent political shift with President Biden stepping down and the rising odds of a Trump victory, who is known for his pro-business stance, might be bolstering investor sentiment. Bargain hunting in previously beaten-down stocks and a favorable economic outlook further contribute to the market's upward momentum.
Read Also: <a href="https://www.benzinga.com/news/24/07/39886242/whats-going-on-with-at-t-stock">What&#8217;s Going On With AT&amp;T Stock?</a>
<h2 class="wp-block-heading">Why This Matters To RIVN Investors</h2>
If the Federal Reserve decides to cut interest rates, it generally lowers borrowing costs for companies. For an automaker like Rivian, which is heavily investing in research and development as well as scaling up production, reduced interest rates can lower the cost of financing, potentially boosting investor confidence in its future profitability.
With President Biden stepping down and expectations of a market rebound due to a healthier reporting season, investors might start looking for growth opportunities in stocks that were previously beaten down. Rivian, as a relatively newer and high-growth company, could attract interest from bargain hunters seeking to capitalize on future growth potential.
Read Also: <a href="https://www.benzinga.com/government/24/07/39878618/whats-going-on-with-alibaba-and-other-chinese-stocks-on-monday">What&#8217;s Going On With Alibaba And Other Chinese Stocks On Monday?</a>
<h2 class="wp-block-heading">Is RIVN A Good Stock To Buy?</h2>
Wall Street analysts view Rivian Automotive on the whole as a Neutral, given the history of coverage over the past three months. Colin Langan from Wells Fargo in Rivian Automotive is the most optimistic, expecting a 80.0% rise in the stock in the coming year.
But looking at how the market as a whole thinks of the stock, you can reference historical price action for views on whether investors feel strongly about the stock one way or another. In the past 3 months, Rivian Automotive rose 85.82%, which indicates that opinion improved on the business and how attractive it is to own based on either its stock price, or underlying fundamentals, like revenue, which rose 82.15% over the past year.
A complete overview of how Wall Street views individual stocks is available <a href="https://www.benzinga.com/analyst-stock-ratings">here</a>, while real time updates on the latest analyst actions will be delivered via <a href="https://pro.benzinga.com">Benzinga PRO</a>. Try it for free.
RIVN has a 52-week high of $28.06 and a 52-week low of $8.26.

News

RIVN

What's Going On With Rivian (RIVN) Stock?

Morgan Stanley (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MS#NYSE">MS</a>) has outperformed the market over the past 10 years by 1.16% on an annualized basis producing an average annual return of 12.08%. Currently, Morgan Stanley has a market capitalization of $165.28 billion. 
Buying $1000 In MS: If an investor had bought $1000 of MS stock 10 years ago, it would be worth $3,087.09 today based on a price of $102.09 for MS at the time of writing.
<h3>Morgan Stanley's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1721676621_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

$1000 Invested In Morgan Stanley 10 Years Ago Would Be Worth This Much Today

CRH (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRH#NYSE">CRH</a>) has outperformed the market over the past 5 years by 6.89% on an annualized basis producing an average annual return of 19.83%. Currently, CRH has a market capitalization of $55.14 billion. 
Buying $100 In CRH: If an investor had bought $100 of CRH stock 5 years ago, it would be worth $247.03 today based on a price of $80.71 for CRH at the time of writing.
<h3>CRH's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1721676616_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much You Would Have Made Owning CRH Stock In The Last 5 Years

Comcast Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMCSA#NASDAQ">CMCSA</a>) shares are trading lower by 1.67% to $39.41 Monday. Shares of several telecom stocks are trading lower in sympathy with Verizon Communications Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VZ#NYSE">VZ</a>) after the company reported worse-than-expected <a href="https://www.benzinga.com/pressreleases/24/07/g39879464/verizon-delivers-strong-wireless-service-revenue-and-broadband-subscriber-growth-in-q2">second-quarter revenue results</a>.
Verizon&#8217;s performance in broadband net additions, with 391,000 new subscribers and a 17.2% increase in broadband customers year-over-year, highlights its growing presence in the broadband market. This increase can intensify competition in the broadband space, potentially impacting Comcast's own broadband subscriber growth and revenue.
Additionally, Verizon&#8217;s consumer segment showed a slight revenue increase of 1.5% year-over-year and a 100 basis point improvement in EBITDA margin. Despite the disappointing revenue results, this indicates Verizon is efficiently managing its consumer business, which could put pressure on Comcast to improve its own performance metrics to stay competitive.
Read Also: <a href="https://www.benzinga.com/news/24/07/39886242/whats-going-on-with-at-t-stock">What&#8217;s Going On With AT&amp;T Stock?</a>
<h2 class="wp-block-heading">How To Buy CMCSA Stock</h2>
Besides going to a brokerage platform to purchase a share &#8211; or fractional share &#8211; of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument. 
For example, in Comcast&#8217;s case, it is in the Communication Services sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.
According to data from&nbsp;<a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, CMCSA has a 52-week high of $47.46 and a 52-week low of $36.43.

CMCSA

Why Comcast (CMCSA) Stock Is Moving During Monday's Session

All eyes could be on Tesla Inc&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) non-vehicle segments and political catalysts when the company reports second-quarter financial results after <a href="https://www.benzinga.com/earnings">market close Tuesday.</a>
Here are the earnings estimates, what analysts are saying and key items to watch.
Earnings Estimates: Analysts expect Tesla to report second-quarter revenue of $24.93 billion, according to data <a href="http://www.benzinga.com/pro/register/?utm_source=BZprocontent072224&amp;t=be2bearmibe3na1">from Benzinga Pro.</a>
Tesla reported revenue of $24.73 billion in last year's second quarter. The company has missed analysts' revenue estimates in three straight quarters.
Analysts expect the company to report second-quarter earnings per share of 62 cents, compared to 91 cents per share in last year's second quarter. The company has missed analysts' earnings per share estimate in three straight quarters.
Read Also: <a href="https://www.benzinga.com/exclusives/24/07/39886192/exclusive-tesla-an-elon-musk-and-a-technology-story-first-ev-story-last-market-strategist-explains-w">EXCLUSIVE: Tesla &#8216;An Elon Musk And A Technology Story First, EV Story Last&#8217; — Market Strategist Explains Why To Buy The Stock</a>
What Analysts Are Saying: Analysts<a href="https://www.benzinga.com/24/07/39623354/tesla-energy-draws-attention-praise-from-analysts-with-potential-ai-boom-gaining-market-share-or-the"> have been mixed</a> on Tesla in recent months. The electric vehicle company beat analysts' estimates for second quarter deliveries.
Tesla reported second-quarter deliveries of 443,956, which was down 4.8% year-over-year and up 14.8% quarter-over-quarter.
A five percent decline in deliveries "never looked so good," Guggenheim analyst Ronald Jewsikow said after the Tesla figure was reported.
The analyst, who had a sell rating, raised the price target from $126 to $134 "with demand headwinds persisting."
Jewsikow was one of several analysts who praised the energy segment for Tesla, with the company now reporting energy storage alongside deliveries and production figures ahead of earnings.
The analyst said Tesla stock is likely moving higher more from the energy storage figure than the delivery figure.
Investors could begin to pay more attention to Tesla Energy, Morgan Stanley analyst Adam Jonas said in a recent note.
The analyst, who had an Overweight rating and $310 price target, said Tesla Energy could be worth $36 per share, or around $130 billion. The analyst sees Gen AI acceleration helping lead to an increase in energy demand, electricity generation, and data center investment.
Wedbush analyst Dan Ives has an Outperform rating and recently raised the price target from $275 to $300.
"After a very choppy start to 2024 for Musk &amp; Co. we believe the Tesla demand story has made a significant turn for the positive with stronger than expected 2Q deliveries this morning [July 2] marking a ‘major turning point' in the Tesla bull case story," Ives said.
Key Items to Watch: Analysts have already dissected the Q2 delivery and production figures, which could lead to less focus on the electric vehicle storyline.
One area of focus could be the Cybertruck, which isn't currently individually broken out in quarterly figures. The company could update on how many it has sold and how many are reserved. Tesla is also nearing delivery of the electric pickup truck <a href="https://www.benzinga.com/news/24/07/39876213/tesla-confirms-it-aims-to-start-selling-cybertruck-in-canada-this-year-pre-orders-open-for-150">in Canada,</a> adding another market to sales.
Outside of vehicles, energy and artificial intelligence could be key focuses as many analysts praised the large energy storage figure reported ahead of the earnings.
Tesla is delaying its robotaxi event, originally set for Aug. 8, until October. The company could share more on what went into the decision and what is expected at the event.
Musk's<a href="https://www.benzinga.com/news/24/07/39804113/exclusive-elon-musk-is-burning-his-own-blue-bridges-by-donating-to-trump-says-market-expert"> recent endorsement of</a> Donald Trump for president in the 2024 election and reports of donations could also be a key focus of questions, with many experts noting that Trump could be bad for the electric vehicle sector.
The Tesla CEO recently said that he supports subsidies going away, as it would benefit the company.
TSLA Price Action: Tesla shares are up 5% to $251.73 on Monday, versus a 52-week trading range of $138.80 to $299.29. Tesla shares are up 1.2% year-to-date in 2024 after gaining 33.9% over the last month, as seen on the<a href="http://www.benzinga.com/pro/register/?utm_source=BZprocontent072224&amp;t=be2bearmibe3na1"> Benzinga Pro chart</a> below.
<figure class="wp-block-image size-full"><a href="http://www.benzinga.com/pro/register/?utm_source=BZprocontent072224&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="997" height="508" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/07/22143207/Screenshot-77.png" alt="" class="wp-image-449431" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/07/22143207/Screenshot-77.png 997w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/07/22143207/Screenshot-77-300x153.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/07/22143207/Screenshot-77-768x391.png 768w" sizes="(max-width: 997px) 100vw, 997px" /></a></figure>
Read Next:
<ul>
<li><a href="https://bzresearch.myclickfunnels.com/latest-research-webinar-redirect-evergreen?utm_source=website-content" target="_blank" rel="noreferrer noopener">Turn Trading Into The Ultimate Side Hustle Using Benzinga Tools In A Free Webinar</a></li>
</ul>
Image created using artificial intelligence via Midjourney.

Analyst Color

Price Target

Previews

Reiteration

Analyst Ratings

Tech

TSLA

Tesla Q2 Earnings Preview: Analyst Estimates, Key Items To Watch, Can 'Major Turning Point' In Bull Case Continue?

Hims &amp; Hers Health Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>) shares are moving higher on Monday after the company appointed former Novo Nordisk COO and President Kåre Schultz&#8216;s <a href="https://www.benzinga.com/quote/HIMS/earnings">to its Board of Directors.</a>
Schultz brings<a href="https://www.benzinga.com/pressreleases/24/07/b39877550/pharmaceutical-industry-chief-k-re-schultz-joins-hims-hers-board"> extensive experience from his leadership roles</a> at Novo Nordisk Inc.  (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>), Teva Pharmaceutical Industries LTD (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEVA#NYSE">TEVA</a>) and Lundbeck. 
At Novo Nordisk, Schultz was instrumental in establishing the company as a leader in diabetes care. 
&#8220;Kåre&#8217;s experience gives us an incredible wealth of expertise as we bring together the most valuable elements of clinical excellence, healthcare and technology to redefine health and wellness for our customers.&#8221; said CEO Andrew Dudum.
Price Action: Hims &amp; Hers shares were up by 5.12% at $20.50 at the time of writing, according to<a href="https://pro.benzinga.com/dashboard"> Benzinga Pro.</a>
<figure class="wp-block-image size-large is-resized"><a href="http://www.benzinga.com/pro/register/?utm_source=BZprocontent072224&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="1024" height="531" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/07/22151403/HIMS-1024x531.png" alt="" class="wp-image-449530" style="width:489px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/07/22151403/HIMS-1024x531.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/07/22151403/HIMS-300x156.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/07/22151403/HIMS-768x398.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/07/22151403/HIMS.png 1389w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
See Also: 
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/07/39891746/bidens-exit-from-presidential-race-yet-another-curveball-for-equity-investors-analysts">Biden&#8217;s Exit From Presidential Race &#8216;Yet Another Curveball For Equity Investors&#8217;: Analysts</a></li>
</ul>
Image: Courtesy of Hims &amp; Hers Health, Inc.

Movers

Hims & Hers Health, Inc. Class A Common Stock

HIMS

TEVA

Why Hims & Hers Heath Shares Are Surging Today

WIIM

Domino's Pizza shares are trading higher amid a possible rebound after the stock last week fell after the company reported mixed Q2 results.

Delta CEO Says Worst Disruptions Will Take A Few More Days To Clear; Expects Improvements Today And Further Progress By Tuesday And Wednesday; Delta Team Working Around The Clock To Restore Operations

Director of the U.S. Secret Service (USSS) Kimberly Cheatle appeared before the House Oversight Committee on Monday following a nationwide call for answers following the attempted assassination of former President <a href="https://www.benzinga.com/government/24/07/39778541/trump-shooting-recalls-memories-of-reagan-assassination-attempt-heres-how-markets-react-to-political">Donald Trump on July 13</a>.
Hearing Takeaways: Cheatle offered vague commentary on the implications of the attempt. The director said that the USSS &#8220;will move heaven and earth&#8221; to make sure that an event like the one on July 13 would not happen again.
&#8220;We failed,&#8221; Cheatle said in her opening statement. 
During an aggressive line of questioning by Nancy Mace (R-SC), Cheatle agreed that the attempt was &#8220;preventable.&#8221;
Several representatives — including committee chair James Comer (R-KY), Jared Moskowitz (D-FL), Ro Khanna (D-CA), Andy Biggs (R-AZ) and others — called on Cheatle to resign her post.
&#8220;I think I am the best person to lead the Secret Service at this time," Cheatle said under questioning by Virginia Foxx (R-VA).
Cheatle repeatedly insisted that she would not comment on specifics until an investigation was concluded. 
Representatives Alexandria Ocasio-Cortez (D-NY), Jim Jordan (R-OH), Summer Lee (D-PA), Gary Palmer (R-AL), Byron Donalds (R-FL) and Moskowitz each expressed incredulity that the Secret Service allowed the gunman to perch on a roof at shooting range to the stage where Trump was speaking. 
Cheatle confirmed to Kweisi Mfume (D-MD) that there was &#8220;overwatch&#8221; on the building on July 13.
<a href="https://www.benzinga.com/news/24/07/39873874/trumps-pleas-for-extra-security-repeatedly-ignored-by-secret-service-prior-to-assassination-attempt">Previous reporting indicated</a> that the Secret Service denied requests by the Trump campaign for additional security at campaign events. Cheatle was unable to tell the committee how many times the USSS turned down Trump campaign requests but did say that there are alternate ways to cover requests, whether that be by personnel or technology support. Cheatle told Comer that the assets requested by the Trump campaign for July 13 were given as asked.
Cheatle told Biggs that the USSS identified the perpetrator as suspicious before the attempt and sent agents to interview him but no agents located him. She said that many individuals at rallies are labeled as suspicious, but that doesn't necessarily mean they constitute a threat. When asked by Maxwell Alejandro Frost (D-FL), Cheatle estimated that there were two to five instances of communication to the USSS about the gunman&#8217;s presence before the shooting.
William Timmons (R-SC) insinuated that female USSS agents could not adequately protect Trump. Tim Burchett (R-TN) called Cheatle, the second female director of the USSS, a &#8220;DEI [Diversity, Equity and Inclusion] horror story.&#8221;
&#8220;The incident on the 13th has nothing to do with DEI,&#8221; Cheatle told Jasmine Crockett (D-TX). &#8220;The incident on the 13th has to do with a failure or a gap either with planning or communication.&#8221;
Ayanna Pressley (D-MA) accused her Republican colleagues of willfully spreading misinformation and engaging in misogyny and racism.
Ranking member Jamie Raskin (D-MD), Rashida Tlaib (D-MI), Gerry Connolly (D-VA) and non-voting delegate Eleanor Holmes Norton (D-DC) railed against the AR-15 weapon used by the shooter and pushed for stricter gun laws. Crockett tied the shooting to Pennsylvania&#8217;s status as an open-carry state.
Now Read:
<ul>
<li><a href="https://www.benzinga.com/general/politics/24/07/39886916/harris-vs-trump-can-bidens-vp-defeat-former-president-head-to-head-polls-reveal-close-race">Harris Vs. Trump: Can Biden&#8217;s VP Defeat Former President? Head-To-Head Polls Reveal Close Race</a></li>
</ul>
Image: Shutterstock

Politics

'We Failed' During Trump Assassination Attempt: Secret Service's Kimberly Cheatle Grilled By Oversight Committee

Lockheed Martin And Slovak Republic Announce Arrival Of First F-16 Block 70s In Slovakia; All 14 F-16s To Be Delivered By End Of 2025

GOOG

GOOGL

Google To Introduce Choice Experience In Chrome Instead Of Deprecating Third-Party Cookies; Will Continue Developing Privacy Sandbox APIs For Enhanced Privacy And Utility; Plans To Add IP Protection To Incognito Mode

A recent survey from Northwestern Mutual revealed that Americans believe they <a href="https://www.benzinga.com/personal-finance/24/06/39193206/retirement-savings-goal-surges-1-46-million-now-seen-as-magic-number">need about $1.46 million to retire comfortably</a>. This figure has jumped 15% in just a year and represents a staggering 53% increase since 2020. It's clear that many people feel pressure to save an astronomical amount for retirement – but is this really what you need?
Don't Miss:
<ul>
<li>The average American couple has saved this much money for retirement —<a href="http://www.benzinga.com/money/smartasset"> How do you compare</a>?</li>
<li>How much money will a $200,000 annuity pay out each month?<a href="https://www.benzinga.com/money/200k-annuities-adv"> The numbers may shock you.</a></li>
</ul>
Andrew Biggs, a senior fellow at the American Enterprise Institute, is challenging the status quo with a bold claim: you might be able to retire with as little as $50,000 to $100,000 in total savings. That's a far cry from the million-dollar benchmark many financial experts advocate and the amount people think they need.&nbsp;
In his Wall Street Journal opinion piece, "You Don't Need to be a Millionaire to Retire," Biggs explains the <a href="https://www.benzinga.com/personal-finance/24/07/39819250/do-you-know-how-much-you-should-have-in-your-401-k-heres-what-experts-recommend-vs-the-actual-av">average American has only saved</a> around $88,400 for retirement. He argues that despite what surveys say, hard data on retirees show it takes far lower levels of savings to be financially secure in retirement.&nbsp;
Contrary to widespread concerns about retirees struggling financially, recent data paints a more optimistic picture. According to Biggs&#8217; analysis of the Federal Reserve&#8217;s Survey of Household Economics and Decision-Making, most older Americans appear to be managing well in retirement.
Trending: Rory McIlroy&#8217;s mansion in Florida is worth $22 million today, doubling from 2017 —<a href="https://benzinga.com/money/rory-mcilroys-florida-mansion-doubled-in-value"> here&#8217;s how to get started investing in real estate with just $100</a>
The survey asked U.S. households about their financial situation and revealed some encouraging trends for those aged 65 to 74. Between 2019 and 2022, 86% of respondents in this age group reported &#8220;doing OK&#8221; or &#8220;living comfortably.&#8221; Specifically, 49% said they were &#8220;living comfortably,&#8221; while 37% reported &#8220;doing OK.&#8221;
Only a small fraction of retirees in this age range indicated financial distress. About 12% stated they were &#8220;just getting by,&#8221; and a mere 3% reported &#8220;finding it difficult to get by.&#8221; This suggests that the reality of retirement for many Americans may be more positive than often portrayed in public discourse.
Biggs also points out a particularly useful question: "Approximately how much do you currently have saved for retirement?" The categories ranged from "less than $10,000" to "more than $1 million."
See Also: <a href="https://www.benzinga.com/money/retire-5mil-nest-egg">Can you guess how many retire with a $5,000,000 nest egg? &#8211; How does it compare to the average?</a>
Only 19% of retirees reported having less than $10,000 in savings. This figure challenges Sen. Bernie Sanders's claim that "almost 45% of older Americans between the ages of 55 and 64 have no savings at all and no idea how they will be able to retire with any shred of dignity or respect." Among those finding it difficult to get by, nearly 75% had less than $10,000 in savings. Yet, a slight majority of retirees in this category (52%) reported being either "doing OK" or "living comfortably."
For seniors with more than $10,000 in retirement savings, fewer than 1% said they were struggling financially, while 93% indicated they were "doing OK" or "living comfortably." Among those with $50,000 to $99,999 in savings – a figure much lower than many financial advisors suggest – only 3% reported difficulty getting by, 11% were just getting by, and 86% were either "doing OK" or "living comfortably."
See Also: Will the surge continue or decline on real estate prices?<a href="https://www.benzinga.com/money/realbricks"> People are finding out about risk-free real estate investing that lets you cash out whenever you want.</a>
Biggs&#8217; analysis reveals that many retirees report financial comfort with savings between $50,000 and $100,000. This suggests that not having a <a href="https://www.benzinga.com/personal-finance/24/05/38875764/can-you-guess-how-many-americans-have-2-million-saved-for-retirement-its-probably-less-than-youd">million-dollar nest egg</a> isn&#8217;t necessarily a cause for panic or a reason to believe retirement is impossible. Biggs&#8217; opinions are based on a survey of current retirees&#8217; actual experiences, which often differ significantly from pre-retirees' expectations or fears about future needs.
In his WSJ piece, Biggs emphatically states, &#8220;It&#8217;s impossible to find any evidence that seniors need even a fraction of $1.46 million in savings to be financially secure.&#8221; Whether you need $50,000, ten times your annual earnings, or even millions, it's a good idea to <a href="https://www.benzinga.com/money/fam">consult a financial advisor</a>. They can help create a realistic savings goal for you and your needs.&nbsp;
Read Next:
<ul>
<li>Many are surprised by Mark Cuban&#8217;s advice for lotto winners:<a href="https://www.benzinga.com/money/mark-cubans-annuity-adv"> Cash or annuity?</a></li>
<li>Can you guess how many Americans successfully retire with $1,000,000 saved?<a href="https://www.benzinga.com/money/red-ventures"> The percentage may shock you</a>.</li>
</ul>

Personal Finance

Top Economist Debunks Myth You Need $1.46 Million To Retire – Argues You Can Retire Comfortably With $100,000 Or Less

ENTG

FORM

MCHP

MKSI

MPWR

MRVL

NXPI

RMBS

SLAB

SWKS

Shares of semiconductor stocks are trading higher as the sector rebounds after falling last week. Chip stocks droped last week amid possible profit taking and concerns over new China restrictions. Investors may also be weighing Biden's exit from the 2024 presidential race.

Activist Indaba Reportedly Amasses Stake In Equity Commonwealth

Needham initiated coverage on Axsome Therapeutics Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXSM#NASDAQ">AXSM</a>), which focuses on central nervous disorders conditions, including depression, Alzheimer&#8217;s disease agitation, migraine, <a target="_blank" href="https://www.benzinga.com/quote/axsm" rel="noreferrer noopener">narcolepsy, and fibromyalgia</a>.&nbsp;
Needham writes that Axsome Therapeutics&#8217; diversified CNS portfolio will help grow the risk-adjusted topline by 8-10x in five years.
The analyst anticipates an upside for Axsome Therapeutics on its two marketed drugs, Auvelity for major depressive disorder and Sunosi for excessive daytime sleepiness.
Related: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/01/36788978/axsome-depression-drugs-commercial-success-pipeline-potential-undervalued-analyst-says" rel="noreferrer noopener">Axsome Depression Drug&#8217;s Commercial Success, Pipeline Potential Undervalued, Analyst Says</a>.
Physicians report a positive experience with Auvelity due to its novel mechanism of action, rapid onset, and efficacy. However, they note that payer coverage could be better. Physicians were generally positive about increasing their use of Auvelity, but Needham does not anticipate better-than-expected growth for the drug.
Needham initiated with a Buy rating and a <a target="_blank" href="https://www.benzinga.com/quote/AXSM/analyst-ratings" rel="noreferrer noopener">price target of $130</a>.
The analyst says the company&#8217;s most significant pipeline asset, AXS-05 in Alzheimer&#8217;s Disease agitation, is already de-risked based on two positive Phase 3 trial data, and the ADVANCE-2 Ph 3 readout this year will support a filing.
Needham estimates 2028 US sales of ~$550 million (+11% vs. cons), growing to ~$1 billion in 2030
Currently, Axsome receives no value for its remaining pipeline, but several of these products are in the late stages.
Needham anticipates they will contribute to topline growth soon.
Axsome has three late-stage assets: AXS-07 for migraine, AXS-14 for fibromyalgia—2Q24 filing, and <a target="_blank" href="https://www.benzinga.com/general/biotech/24/03/37917570/whats-going-on-neurology-focused-axsome-therapeutics-stock-on-monday" rel="noreferrer noopener">AXS-12 for narcolepsy</a> filing post-second half data safety data, which can collectively drive ~$1 billion in sales by 2030 with a 60-65% probability of success.
Price Action: AXSM stock is up 1.21% at $85.88 at the last check on Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/07/39891005/cassava-sciences-advances-alzheimers-drug-through-high-stakes-phase-3-trials" target="_blank" rel="noreferrer noopener">Cassava Sciences Advances Alzheimer&#8217;s Drug Through High-Stakes Phase 3 Trials</a>.</li>
</ul>

Biotech

Health Care

Initiation

General

AXSM

Axsome Therapeutics' CNS Portfolio Poised for Major Growth - Analyst Predicts Strong Future

CMA Accepts Google's Commitments On Third-Party Cookies

Harris needs the support of a simple majority, or an estimated 1,969 of the 3,936 Democratic delegates, to secure her nomination at the August convention.
- Reuters Citing Sources

Harris Campaign Aims To Secure Enough Delegates For Nomination By End Of Wednesday

Injective's (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/inj/usd">INJ</a>) price has decreased 3.09% over the past 24 hours to $26.29. This is contrary to the coins performance over the past week where it has experienced an up-trend of 17.0%, moving from $22.51 to its current price.
The chart below compares the price movement and volatility for Injective over the past 24 hours (left) to its price movement over the past week (right). The gray bands are Bollinger Bands, measuring the volatility for both the daily and weekly price movements. The wider the bands are, or the larger the gray area is at any given moment, the larger the volatility.
<img src="https://www.benzinga.com/files/images/story/2024/1721674944_0.png" alt="price_chart" />
The trading volume for the coin has risen 37.0% over the past week diverging from the circulating supply of the coin, which has decreased 0.25%. This brings the circulating supply to 97.15 million. According to our data, the current market cap ranking for INJ is #42 at $2.55 billion.
<img src="https://www.benzinga.com/files/images/story/2024/1721674944_1.png" alt="supply_and_vol" />
<a href="https://www.coingecko.com/en/api">Powered by CoinGecko API</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Markets

$INJ

Cryptocurrency Injective Down More Than 3% Within 24 hours

Canopy Growth Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGC#NASDAQ">CGC</a>) shares are trading higher Monday. Cannabis stocks have gained recently as optimism regarding potential federal policy changes grows.  Investors also assess Biden&#8217;s announcement that he will exit <a href="https://www.benzinga.com/markets/cannabis/24/07/39874209/joe-biden-drops-out-what-would-happen-with-cannabis-legalization-under-kamala-harris-or-donald-t">the 2024 presidential race.</a> 
The Details:
Optimism is growing among cannabis investors following a series of political developments in the United States. Mostly recently, President Joe Biden suspended his campaign and endorsed Vice President Kamala Harris as the Democratic Presidential candidate on Sunday.&nbsp;
Investors may be encouraged by the prospect of a Kamala Harris Presidential candidacy as she has been an <a href="https://www.politico.com/news/2024/03/15/vice-president-to-hold-cannabis-roundtable-00146564">outspoken proponent</a> of the decriminalization of marijuana. Harris called the current classification of marijuana under federal law "absurd" during a White House event in March and said she is looking forward to seeing the Drug Enforcement Administration&#8217;s decision about moving it to a different category.&nbsp;
Read Next: <a href="https://www.benzinga.com/news/24/07/39860370/serve-robotics-stock-rises-after-nvidia-discloses-10-stake">Serve Robotics Stock Rises After Nvidia Discloses 10% Stake</a>
Canopy Growth shares also rose <a href="https://www.benzinga.com/markets/cannabis/24/07/39805320/what-happened-with-canopy-growth-stock-today">last week </a>following the selection of Sen. J.D. Vance (R-Ohio) as Donald Trump's Vice-Presidential running-mate.&nbsp;
According to a Marijuana Moment<a href="https://www.marijuanamoment.net/where-trumps-vice-presidential-running-mate-j-d-vance-stands-on-marijuana/"> report</a>, Vance believes states should set their own cannabis laws. He's also suggested that he&#8217;s against incarcerating individuals for low-level possession.
According to data from <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, Canopy Growth shares are trading about even with the stock&#8217;s 50-day moving average of $7.81, and the company will report its first-quarter results in early August.&nbsp;
<h2 class="wp-block-heading">Should I Sell My CGC Stock?</h2>
When deciding to hold on to or sell a stock, investors should consider their time horizon, unrealized gains and total return.
Shares of Canopy Growth have increased by 99.01% in the past year. An investor who bought shares of Canopy Growth at the beginning of the year would make a profit of $3.07 per share if they sold it today. The stock has risen 12.37% over the past month, meaning an investor who bought shares on June 1 would see a capital loss of $0.16.
Investors may also consider market dynamics. The Relative Strength Index can be used to indicate whether a stock is overbought or oversold. Canopy Growth stock currently has an RSI of 69.09, indicating neutral conditions.
For access to advanced charting and analysis tools and stock data, check out <a href="https://pro.benzinga.com/">Benzinga PRO. Try it for free.</a> 
CGC Price Action: According to <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, Canopy Growth shares are up 11.1% at $7.92 at the time of publication Monday.
Read Also:
<ul>
<li><a href="https://www.benzinga.com/news/24/07/39865576/whats-going-on-with-rivian-stock">What&#8217;s Going On With Rivian Stock?</a></li>
</ul>
Image: Pixabay

Cannabis

What's Going On With Canopy Growth Stock?

Cantor Fitzgerald analyst Yi Fu Lee reiterates Datadog (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DDOG#NASDAQ">DDOG</a>) with a Overweight and maintains $150 price target.

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Comments

GPL Hldgs

News

Latest news for GPL Hldgs (OTC:GPLL) Stock